Compare · BGLC vs HUM
BGLC vs HUM
Side-by-side comparison of BioNexus Gene Lab Corp (BGLC) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BGLC and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $51.90B, about 14489.8x BGLC ($3.6M).
- HUM has been more active in the news (12 items in the past 4 weeks vs 2 for BGLC).
- HUM has more recent analyst coverage (25 ratings vs 0 for BGLC).
- Company
- BioNexus Gene Lab Corp
- Humana Inc.
- Price
- -
- -
- Market cap
- $3.6M
- $51.90B
- 1M return
- -
- +7.44%
- 1Y return
- -
- +45.59%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 12
- Recent ratings
- 0
- 25
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest BGLC
- SEC Form 8-K filed by BioNexus Gene Lab Corp
- RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
- Chief Executive Officer Tan Lee Su-Leng was granted 338,709 shares (SEC Form 4)
- Director Yap Chee Keong was granted 32,258 shares (SEC Form 4)
- Director Bin Abdul Hamid Muhammad Azrul was granted 32,258 shares (SEC Form 4)
- Chief Financial Officer Chong Set Fui was granted 96,774 shares (SEC Form 4)
- Director Low Jook Yuen was granted 16,129 shares, increasing direct ownership by 1,279% to 17,390 units (SEC Form 4)
- SEC Form 10-Q filed by BioNexus Gene Lab Corp
- New insider Fidelion Diagnostics Pte. Ltd. claimed ownership of 392,329 shares (SEC Form 3)
- New insider Tan Lee Su-Leng claimed no ownership of stock in the company (SEC Form 3)
Latest HUM
- Humana Announces New Strategic Joint Venture with BlackRock to Manage CenterWell Senior Primary Care Clinics
- SEC Form 8-K filed by Humana Inc.
- Humana Inc. to Release Third Quarter 2026 Results on November 6, 2026
- Humana upgraded by Raymond James with a new price target
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- Humana upgraded by Robert W. Baird with a new price target
- Humana Announces Improved CMS Star Ratings with 95 Percent of Medicare Advantage Members in 4-Star or Above Plans for 2027
- SEC Form 8-K filed by Humana Inc.
- Humana upgraded by Cantor Fitzgerald with a new price target
- Humana Generates Nearly $20 Billion in Economic Impact Across Kentucky, New Report Finds